Comments on: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease

Comments on: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease https://insideout.vn/sosei-heptares-doses-first-subject-in-phase-1-trial-with-htl0033744-an-ep4-agonist-for-inflammatory-bowel-disease/ Inside Out Thu, 21 Mar 2024 00:05:00 +0000 hourly 1 https://wordpress.org/?v=6.6.2